Canada markets closed

Codexis, Inc. (CDXS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.1900+0.0400 (+1.27%)
At close: 04:00PM EDT
3.0600 -0.13 (-4.08%)
After hours: 07:59PM EDT

Codexis, Inc.

200 Penobscot Drive
Redwood City, CA 94063
United States
650 421 8100

Full Time Employees174

Key Executives

NameTitlePayExercisedYear Born
Dr. Stephen George Dilly MBBS, Ph.D.President, CEO & Director1.88MN/A1960
Mr. Sriram Ryali M.B.A.Chief Financial Officer770.45kN/A1981
Mr. Kevin Norrett M.B.A., M.S.Chief Operating Officer739.56kN/A1973
Carrie McKimDirector of Investor RelationsN/AN/AN/A
Ms. Margaret Nell Fitzgerald J.D.Chief Legal & Compliance Officer, General Counsel and Secretary300.03kN/A1971
Ms. Karen Frechou-ArmijoSenior VP & Head of Human ResourcesN/AN/AN/A
Dr. Stefan Lutz Ph.D.Senior Vice President of ResearchN/AN/AN/A
Mr. Robert Sato M.B.A., Ph.D.Senior Vice President of Pharmaceutical Development, Quality & RegulatoryN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Corporate Governance

Codexis, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 5. The pillar scores are Audit: 4; Board: 3; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.